These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

285 related articles for article (PubMed ID: 11147388)

  • 1. The need for an iterative process for assessing economic outcomes associated with SSRIs.
    Skaer TL; Sclar DA; Robison LM; Galin RS
    Pharmacoeconomics; 2000 Sep; 18(3):205-14. PubMed ID: 11147388
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Antidepressant pharmacotherapy: a review of pharmaco-economic research].
    Sclar DA; Pharm B; Skaer TL; Pharm D; Robinson LM
    Encephale; 1999; 25(5):373-80. PubMed ID: 10598299
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Economic appraisal of antidepressant pharmacotherapy: critical review of the literature and future directions.
    Sclar DA; Skaer TL; Robison LM; Stowers JK
    Depress Anxiety; 1998; 8 Suppl 1():121-7. PubMed ID: 9809224
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The economics of selective serotonin reuptake inhibitors in depression: a critical review.
    Frank L; Revicki DA; Sorensen SV; Shih YC
    CNS Drugs; 2001 Jan; 15(1):59-83. PubMed ID: 11465013
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A randomised controlled trial to compare the cost-effectiveness of tricyclic antidepressants, selective serotonin reuptake inhibitors and lofepramine.
    Peveler R; Kendrick T; Buxton M; Longworth L; Baldwin D; Moore M; Chatwin J; Goddard J; Thornett A; Smith H; Campbell M; Thompson C
    Health Technol Assess; 2005 May; 9(16):1-134, iii. PubMed ID: 15876362
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A multinational pharmacoeconomic evaluation of acute major depressive disorder (MDD): a comparison of cost-effectiveness between venlafaxine, SSRIs and TCAs.
    Doyle JJ; Casciano J; Arikian S; Tarride JE; Gonzalez MA; Casciano R
    Value Health; 2001; 4(1):16-31. PubMed ID: 11704969
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Are SSRIs a cost-effective alternative to tricyclics?
    Hotopf M; Lewis G; Normand C
    Br J Psychiatry; 1996 Apr; 168(4):404-9. PubMed ID: 8730935
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Economic evaluation of antidepressive agents: a systematic critique of experimental and observational studies.
    Barbui C; Percudani M; Hotopf M
    J Clin Psychopharmacol; 2003 Apr; 23(2):145-54. PubMed ID: 12640216
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Economic outcomes with antidepressant pharmacotherapy: a retrospective intent-to-treat analysis.
    Sclar DA; Skaer TL; Robison LM; Galin RS; Legg RF; Nemec NL
    J Clin Psychiatry; 1998; 59 Suppl 2():13-7. PubMed ID: 9559755
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The economic impact of introducing serotonin-noradrenaline reuptake inhibitors into the Brazilian national drug formulary: cost-effectiveness and budget-impact analyses.
    Machado M; Iskedjian M; Ruiz IA; Einarson TR
    Pharmacoeconomics; 2007; 25(11):979-90. PubMed ID: 17960955
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Pharmacoeconomic analysis of venlafaxine in the treatment of major depressive disorder.
    Einarson TR; Addis A; Iskedjian M
    Pharmacoeconomics; 1997 Aug; 12(2 Pt 2):286-96. PubMed ID: 10170453
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Lithium or an atypical antipsychotic drug in the management of treatment-resistant depression: a systematic review and economic evaluation.
    Edwards SJ; Hamilton V; Nherera L; Trevor N
    Health Technol Assess; 2013 Nov; 17(54):1-190. PubMed ID: 24284258
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Economic outcomes associated with tricyclic antidepressant and selective serotonin reuptake inhibitor treatments for depression.
    Crown WH
    Acta Psychiatr Scand Suppl; 2000; 403():62-6. PubMed ID: 11019937
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Antidepressants for people with epilepsy and depression.
    Maguire MJ; Weston J; Singh J; Marson AG
    Cochrane Database Syst Rev; 2014 Dec; 2014(12):CD010682. PubMed ID: 25464360
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Health economic evaluations of antidepressants: a review.
    Hylan TR; Buesching DP; Tollefson GD
    Depress Anxiety; 1998; 7(2):53-64. PubMed ID: 9614592
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Antidepressants for people with epilepsy and depression.
    Maguire MJ; Marson AG; Nevitt SJ
    Cochrane Database Syst Rev; 2021 Apr; 4(4):CD010682. PubMed ID: 33860531
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Cost-effectiveness and cost-utility of tricyclic antidepressants, selective serotonin reuptake inhibitors and lofepramine: randomised controlled trial.
    Kendrick T; Peveler R; Longworth L; Baldwin D; Moore M; Chatwin J; Thornett A; Goddard J; Campbell M; Smith H; Buxton M; Thompson C
    Br J Psychiatry; 2006 Apr; 188():337-45. PubMed ID: 16582060
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Newer generation antidepressants for depressive disorders in children and adolescents.
    Hetrick SE; McKenzie JE; Cox GR; Simmons MB; Merry SN
    Cochrane Database Syst Rev; 2012 Nov; 11(11):CD004851. PubMed ID: 23152227
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Choosing an antidepressant: effectiveness based pharmacoeconomics.
    Stewart A
    J Affect Disord; 1998 Mar; 48(2-3):125-33. PubMed ID: 9543201
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Are SNRIs more effective than SSRIs? A review of the current state of the controversy.
    Thase ME
    Psychopharmacol Bull; 2008; 41(2):58-85. PubMed ID: 18668017
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.